title: Effect of long-term intranasal oxytocin on sexual dysfunction in premenopausal and postmenopausal women: a randomized trial.
abstract: OBJECTIVE
  To assess the effect of on-demand intranasal oxytocin administration on female sexual function and activity.
  
  
  METHODS
  Randomized, prospective, double-blind, placebo-controlled, crossover trial with duration of 22 weeks.
  
  
  METHODS
  Academic medical center.
  
  
  METHODS
  Thirty pre-and postmenopausal women with sexual dysfunction.
  
  
  METHODS
  Over 8 weeks, intranasal oxytocin (32 IU) or placebo self-administered by women within 50 minutes before sexual intercourse; after a washout period of 2 weeks, crossover with patients switched to the alternate group for another 8 weeks.
  
  
  METHODS
  Primary outcome parameter: Female Sexual Function Index (FSFI); secondary outcome parameters: Female Sexual Distress Scale (FSDS), Sexual Quality of Life-Female (SQOL-F), Sexual Interest and Desire Inventory-Female (SIDI-F), and Hamilton depression scale (HDS).
  
  
  RESULTS
  After oxytocin and placebo, the FSFI score increased by 26% and 31%, SQOL-F score by 144% and 125%, and SIDI-F score by 29% and 23%, respectively (repeated measures analysis of variance between groups). After oxytocin and placebo, the FSDS score decreased by 36% and 45%, respectively (repeated measures analysis of variance between groups). There was no statistically significant treatment, sequence (placebo first/second), or interaction effect.
  
  
  CONCLUSIONS
  Long-term intranasal oxytocin and placebo administration both improved sexual function and symptoms of depression in women over time with no treatment, sequence (placebo first/second), or interaction effect.
  
  
  BACKGROUND
  NCT02229721.
authors.affiliation: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; Department of Gynecologic Endocrinology and Reproductive Medicine, Medical University of Vienna, Vienna, Austria.
authors.forename: Dana A
authors.initials: DA
authors.lastname: Muin
authors.affiliation: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
authors.forename: Michael
authors.initials: M
authors.lastname: Wolzt
authors.affiliation: Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
authors.forename: Rodrig
authors.initials: R
authors.lastname: Marculescu
authors.affiliation: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
authors.forename: Safoura
authors.initials: S
authors.lastname: Sheikh Rezaei
authors.affiliation: Department of Thoracic Surgery, Otto-Wagner-Spital, Vienna, Austria.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Salama
authors.affiliation: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
authors.forename: Carola
authors.initials: C
authors.lastname: Fuchs
authors.affiliation: Department of Endocrinology and Metabolism, University Clinic of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
authors.forename: Anton
authors.initials: A
authors.lastname: Luger
authors.affiliation: Academy of Sexual Health, Vienna, Austria.
authors.forename: Elia
authors.initials: E
authors.lastname: Bragagna
authors.affiliation: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
authors.forename: Brigitte
authors.initials: B
authors.lastname: Litschauer
authors.affiliation: Department of Endocrinology and Metabolism, University Clinic of Internal Medicine III, Medical University of Vienna, Vienna, Austria. Electronic address: michaela.bayerle-eder@meduniwien.ac.at.
authors.forename: Michaela
authors.initials: M
authors.lastname: Bayerle-Eder
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D000368:Aged; D001317:Austria; D018592:Cross-Over Studies; D003863:Depression / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D010121:Oxytocin / Q000008:administration & dosage* / Q000009:adverse effects; D017698:Postmenopause; D017697:Premenopause; D011446:Prospective Studies; D011788:Quality of Life; D012725:Sexual Behavior / Q000187:drug effects*; D012735:Sexual Dysfunction, Physiological / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D020018:Sexual Dysfunctions, Psychological / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010121:Oxytocin
keywords: Depression; female sexual dysfunction; orgasm; oxytocin; placebo